Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
ASX:MYX
Price:
7.01 AUD
-1.54%
Market Closed
Updated:
May 12, 2024
EV/OCF
Enterprise Value to OCF
Enterprise Value to OCF
-30.6
Current
-25.9
Median
16.4
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
EV/OCF
=-30.6
Enterprise Value
/
447.8m
Operating Cash Flow
-14.6m
All Countries
| Market Cap | EV/OCF | ||||
|---|---|---|---|---|---|
| AU |
|
Mayne Pharma Group Ltd
ASX:MYX
|
569.5m AUD | -30.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 438.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.3B USD | 202.5 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 42.2 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 930.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.8B USD | 15.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
329.4B USD | 24.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
191.8B GBP | 248.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
180.6B CHF | 15.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
179.5B CHF | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.1B USD | 24.7 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A
You don't have any saved screeners yet
